D. Boral Capital Raises Price Target on Anixa Biosciences to $10
Anixa Biosciences receives a new 'buy' rating and a $10 price target from D. Boral Capital, a 257.14% upside from the current price.
Key Points
- D. Boral Capital raised its price target on Anixa Biosciences to $10 on June 30, 2026, while maintaining a 'buy' rating.
- D. Boral Capital's $10 price target implies 257.14% upside from Anixa Biosciences, Inc.'s ($ANIX) current $2.80 share price.
- Shares of NasdaqCM:ANIX traded near $2.85 on Wednesday, with a market cap of about $94.9 million.
- Vanguard Capital Management opened a new position in Anixa Biosciences with 1,314,982 shares valued at around $3.39 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
D. Boral Capital has raised its price target for Anixa Biosciences, Inc. (NasdaqCM:ANIX) to $10 while maintaining a 'buy' rating. This update came on June 30, 2026, from analyst Jason Kolbert.
D. Boral Capital vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Anixa Biosciences, Inc. Stock Down 19.5%
Shares of Anixa Biosciences, Inc. traded near $2.85 on Wednesday. The company, which is listed on the NasdaqCM, has a market cap of approximately $94.9 million. Anixa is not currently profitable, with a forward P/E ratio of -9.0. The stock has seen a 52-week low of $2.32 and a high of $5.46, with a 50-day moving average of $2.79 and a 200-day moving average of $3.30. The company maintains a strong liquidity position with a current ratio of 9.788 and a quick ratio of 9.155.
$ANIX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Anixa Biosciences, Inc.
Recent insider activity at Anixa Biosciences includes several purchases. On June 16, 2026, Titterton Lewis Jr bought 2,836 shares at an average price of $2.64 per share. Earlier, on June 12, 2026, CEO Amit Kumar acquired 21,000 shares at $2.50 each. In January, Arnold Baskies made multiple purchases, including 10,000 shares at $3.04 each, and earlier in the year, he bought 25,000 shares.
Analysts Set New Price Targets
On June 30, 2026, D. Boral Capital assumed coverage on Anixa Biosciences with a 'buy' rating and a $10 price target. This aligns with the consensus target mean price of $10, supported by three analyst opinions.
Other Institutional Activity in Anixa Biosciences
Vanguard Capital Management LLC recently opened a new position in Anixa Biosciences, acquiring 1,314,982 shares valued at around $3.39 million. Meanwhile, UBS Group AG increased its holdings by 92,564 shares, resulting in a total of 551,637 shares worth approximately $1.42 million, marking a 20.2% increase. Geode Capital Management, LLC also added 13,816 shares, bringing its total to 364,731 shares valued at $941,440.
About Anixa Biosciences
Anixa Biosciences, Inc. is a biotechnology company based in San Jose, California. It focuses on developing therapies and vaccines targeting unmet needs in oncology, including a chimeric endocrine receptor-T cell therapy for ovarian cancer and a breast cancer vaccine. Led by CEO Dr. Amit Kumar, the company aims to address various intractable cancers through its innovative vaccine technologies.
Bottom Line
D. Boral Capital's recent rating and price target increase for Anixa Biosciences highlights continued interest in the company's potential. With a focus on innovative cancer therapies and vaccines, Anixa remains a company to watch. As always, it's important to remember that these ratings are based on past and current data, and future performance can vary.
Get Anixa Biosciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ANIX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.